REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · IEX Real-Time Price · USD
14.35
0.00 (0.00%)
At close: May 31, 2024, 4:00 PM
14.38
+0.03 (0.21%)
After-hours: May 31, 2024, 6:59 PM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $86.73M in the twelve months ending March 31, 2024, down -20.90% year-over-year. Revenue in the quarter ending March 31, 2024 was $15.62M, a -18.37% decrease year-over-year. In the year 2023, REGENXBIO had annual revenue of $90.24M, a decrease of -19.94%.
Revenue (ttm)
$86.73M
Revenue Growth
-20.90%
P/S Ratio
8.15
Revenue / Employee
$252,110
Employees
344
Market Cap
706.82M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Embecta | 1.13B |
| Phibro Animal Health | 999.56M |
| The Pennant Group | 575.34M |
| CareDx | 275.11M |
| National Research | 147.42M |
| Exscientia | 25.14M |
| Pliant Therapeutics | 248.00K |
| Lyell Immunopharma | 68.00K |
RGNX News
- 23 days ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 25 days ago - REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 4 weeks ago - REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 5 weeks ago - REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - PRNewsWire
- 2 months ago - REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD - PRNewsWire
- 2 months ago - REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days - PRNewsWire
- 3 months ago - REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants - PRNewsWire
- 3 months ago - REGENXBIO Announces Proposed Public Offering of Common Stock - PRNewsWire